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ABSTR ACT: Choline is an essential nutrient that plays an important role in lipid metabolism and DNA methylation. Studies in rodents suggest
that choline may adversely affect glycemic control, yet studies in humans are lacking. Using the human hepatic and placental cells, HepG2 and BeWo,
respectively, we examined the interaction between choline and glucose treatments. In HepG2 cells, choline supplementation (1 mM) increased global DNA
methylation and DNA methyltransferase expression in both low-glucose (5 mM) and high-glucose (35 mM) conditions. Choline supplementation increased
the expression of peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), which mediates fatty acid β-oxidation, especially in the high-glucose condition. Highglucose exposure increased the transcription of the gluconeogenic gene phosphoenolpyruvate carboxykinase (PEPCK), while choline supplementation mitigated such increase. Compared to HepG2 cells, the placenta-derived BeWo cells were relatively unresponsive to either high-glucose or -choline treatment.
In conclusion, choline and glucose interacted to affect macronutrient metabolic genes, yet there was no indication that choline may worsen glycemic control
in these in vitro human cell culture models.
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Introduction

The essential nutrient choline participates in various biological
processes. It can be derived into phosphatidylcholine, a structural component of lipoproteins, as well as betaine, which
provides methyl groups for transmethylation reactions.1 The
demand for choline increases substantially during pregnancy. Increasing choline intake during pregnancy has been
shown to improve cognitive functions of rodent offspring2,3
and improve maternal and placental angiogenesis and stress
markers in humans.4,5
Despite the potential benefits of choline supplementation
on improving pregnancy outcomes, several rodent studies
suggest that choline may adversely affect glycemic control.6–9
Dietary choline restriction yields better glucose tolerance
despite paradoxical exacerbation of fatty liver either in mice
fed with high-fat diets or in mice with genetic mutations
in choline or energy metabolic genes.6–9 In these rodent
models, choline is suggested to increase glucagon-mediated
gluconeogenesis7 and reduce fatty acid esterification, which
allows for higher hepatic output of free fatty acids,8 a known
contributor to insulin resistance. Additionally, the role of
choline as a methyl donor may modify glycemic control. DNA
cytosine-phosphate-guanine (CpG) hypermethylation is seen
in leukocytes10 and pancreatic β cells11 in cases of insulin

resistance or type 2 diabetes. Choline as a methyl group donor
may further promote such elevation in CpG methylation.
Nevertheless, in vitro or in vivo evidence in humans regarding the interaction between choline and glycemic control is
still lacking.
Pregnancy is characterized by insulin resistance and
increased risk of hyperglycemia.12 The placenta is implicated as a major mediator of gestational diabetes mellitus
as the disease is resolved after the placenta is removed at
delivery.13 In this study, we used a human placental trophoblast cell line BeWo to examine the influence of choline
supplementation and high-glucose exposure on cell growth
and macronutrient metabolism in this gestation-specific
organ. Since the liver is the main location of choline metabolism and is sensitive to insulin and glucagon actions, we also
used the human hepatocellular carcinoma cell line HepG2
to delineate hepatic metabolic changes in response to choline and glucose supplementation. As the enzyme betainehomocysteine S-methyltransferase (BHMT), which transfers
choline-derived methyl groups to the transmethylation cycle,
is predominantly expressed in liver but not in placenta,14 study
of the two aforementioned cell lines helps distinguish the
influence of choline on macronutrient metabolism and epigenetic regulation in modulating glycemic control.
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Methods

Cell culture and treatments. The human hepatocellular
carcinoma cell line HepG2 was kindly provided by
Dr. Jean Grassman (Brooklyn College), and the human choriocarcinoma cell line BeWo was retrieved from the American Type Culture Collection (ATCC). The BeWo cells retain
important characteristics, such as hormone synthesis and
morphology of first-trimester trophoblasts.15
HepG2 cells were maintained in Eagle’s minimum essential medium (MEM) with 2 mM l-glutamine and 10% fetal
bovine serum (FBS). BeWo cells were maintained in Kaighn’s
modification of Ham’s F-12 medium (ATCC® 30-2004™)
with 10% FBS. All cells were incubated in 5% CO2–95% air at
37°C. For the experiments, both HepG2 and BeWo cells were
cultured in six-well cell culture plates and grown in MEM
containing 2.5% FBS. MEM contained 7 µM of choline as
was specified by the manufacturer (Corning), and the 2.5%
FBS contained 16 µM of choline as was reported previously.16
As such, total choline provided by the MEM and 2.5% FBS
was 23 µM. Glucose concentration of the medium was 5 mM
as was specified by the manufacturer. To examine the effects
of glucose and choline supplementation, the low-glucose, lowcholine (LG–LC) group was not provided with additional
glucose or choline, the low-glucose, high-choline (LG–HC)
group was supplemented with 1 mM of choline chloride, the
high-glucose, low-choline (HG–LC) group was supplemented
with 30 mM of glucose in addition to the 5 mM glucose in the
MEM, and the high-glucose, high-choline (HG–HC) group
was supplemented with both 30 mM of glucose and 1 mM of
choline chloride. Cells were seeded at a starting amount of
2 × 105 cells (passages 5–15) per well and cultured for 72 hours
for HepG2 cells and 96 hours for BeWo cells before harvest.
The length of cell culture was determined based on previous
studies16,17 and preliminary experiments, which suggest that
the cells reached 70% confluence at those time points and the
effect of choline and glucose on biomarkers of interest can be
detected. Each experiment was repeated three times.
Cell count and viability. After 72 hours of cell culture
for HepG2 and 96 hours of cell culture for BeWo, culture
medium was removed, and the attached cells were trypsinized,
centrifuged, and resuspended in phosphate-buffered saline.
Cell counts were measured using a hemocytometer, and cell
viability was assessed using the Trypan blue dye exclusion.
RNA extraction, reverse transcription, and quanti
tative real-time polymerase chain reaction (PCR). Total
RNA was extracted from HepG2 and BeWo cells using
TRIzol® (Life Technologies) and chloroform. RNA concentration and integrity were checked using a NanoDrop2000 instrument (Thermo Fisher Scientific). Reverse transcription was
conducted using the high-capacity cDNA reverse transcription
kit (Life Technologies) as per the manufacturer’s instructions.
Quantitative real-time PCR was conducted using SYBR-green
detection in a MiniOpticon real-time PCR system (Bio-Rad).
Expression of the following genes was analyzed: antigen
12
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identified by monoclonal antibody Ki-67 (MKI67), BHMT,
caspase 3 (CASP3), choline dehydrogenase (CHDH), DNA
methyltransferase 1 (DNMT1), DNA methyltransferase 3A
(DNMT3A), fatty acid synthase (FAS), glucose transporter 2
(SLC2A2 or GLUT2), GLUT1 (SLC2A1), glucose-6-phosphate dehydrogenase (G6PD); glycerol-3-phosphate acyltransferase 2 (GPAT2), peroxisomal acyl-coenzyme A oxidase 1
(ACOX1), proliferating cell nuclear antigen (PCNA), and phosphoenolpyruvate carboxykinase (PEPCK). All primers were
designed using GeneRunner Version 3.01 (http://www.softpedia.com) (Supplementary Table 1). The efficiency of each pair
of primers was between 90% and 100%. Data were expressed as
the fold changes in mRNA concentrations of the above genes
relative to the housekeeping gene (β-glucuronidase, GUSB)
using the DDCt method.18
Global DNA methylation. DNA was extracted from
HepG2 and BeWo cells using the GeneJET Genomic DNA
Purification Kit (Thermo Fisher Scientific) as per the manufacturer’s instructions. DNA was treated with nuclease P1, alkaline phosphatase, and phosphodiesterase (Sigma-Aldrich).19
CpG methylation of the samples was quantified using a DNA
methylation enzyme-linked immunosorbent assay (ELISA)
kit (Cayman Chemical) as per the manufacturer’s instructions.
Statistical analysis. Analysis of variance tests followed
by post hoc Bonferroni’s correction were conducted to assess
the differences among the treatment groups. Data not meeting
the normality assumption were log transformed. All analyses
were performed using SPSS (release 22; IBM). Differences
were considered as significant at P , 0.05. Values are presented as mean ± standard error.

Results

Differential effects of choline and glucose on HepG2
and BeWo cell growth. At 72 hours of culture, HepG2 cell
counts did not differ between the HG or LG groups. However,
choline supplementation significantly increased (P , 0.01) the
cell counts regardless of glucose treatment (Fig. 1A). At 96 hours
of culture, BeWo cell counts tended to increase (P = 0.07) moderately in the HG–LC (high-glucose control) group compared
to the LG–LC (low-glucose control) group. However, choline
supplementation in the HG–HC group seemed to alleviate the
growth-promoting effect of glucose and normalize cell counts
to the level of the LG–LC group (Fig. 1B).
In HepG2 cells, mRNA expression of the cellular
proliferative marker KI67 was increased (P , 0.05) by highglucose treatment. Choline supplementation further increased
(P , 0.05) KI67 expression in both low- and high-glucose
groups (Fig. 1C). In BeWo cells, KI67 expression was
suppressed (P , 0.01) by high glucose despite the increased
cell counts at 96 hours of culture, yet its expression was not
altered by choline supplementation (Fig. 1D). The expression
of another cellular proliferative marker, PCNA, and the cellular
apoptotic marker, CASP3, was not altered by glucose or choline
supplementation in BeWo cells.
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Figure 1. Cell numbers (A and B) and expression of cellular proliferative and apoptotic markers (C and D) of HepG2 and BeWo cells after 72 or 96 hours of
cultivation in different choline and glucose concentrations. LG–LC (black bars): low-glucose, low-choline; LG–HC (hatched bars): low-glucose, high-choline; HG–LC
(gray bars): high-glucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05; (b) P , 0.1.
Abbreviations: CASP3, caspase 3; KI67, antigen identified by monoclonal antibody Ki-67; PCNA, proliferating cell nuclear antigen.

Choline supplementation increased DNA meth
ylation of HepG2 cells. Expression of the DNMT1, which
maintains existing DNA methylation marks, and DNMT3A,
which mediates de novo DNA methylation, was examined.
In HepG2, neither methyltransferases were altered by glucose treatment. However, choline supplementation significantly increased (P , 0.05) DNMT1 expression, and further,
the HG–HC group had a higher (P , 0.01 for DNMT1
and P = 0.09 for DNMT3A) expression of those methyltransferases than the LG–HC group, suggesting that choline-mediated increase in methyltransferase expression was
more pronounced in a high-glucose environment (Fig. 2A).
Consistent with the higher DNMT expression, choline
supplementation increased (P , 0.05) global CpG methylation (Fig. 2B). However, DNA methylation was not modified
by glucose treatment in HepG2 cells. In BeWo cells, methyltransferase expression was not altered by glucose or choline
treatment (Fig. 2C), and their global CpG methylation levels
were below the reliable detection limit of the assay kit (data
not shown).

In order for choline to be used as a methyl donor, it
is first oxidized to betaine, which is mediated by the ratelimiting enzyme CHDH. Betaine then donates its labile
methyl group to homocysteine for its remethylation to
methionine. After methionine is converted to the universal
methyl donor S-adenosylmethionine, the choline- or betaine-derived methyl groups can be used in various methylation
reactions. The methyl group transfer of betaine is mediated
by the enzyme BHMT1, which is predominantly expressed
in the liver. Glucose and choline treatments interact to affect
CHDH and BHMT1 expression in HepG2 cells. Choline
supplementation increases CHDH (LG–LC vs LG–HC,
P = 0.01) and BHMT1 (LG–LC vs LG–HC, P , 0.01)
expression in the low-glucose condition but not in the highglucose condition (Fig. 2A).
BeWo cells did not express BHMT1 (data not shown),
and CHDH expression was not altered by choline or glucose
treatment (Fig. 2C). The lack of BHMT in BeWo may explain
the ineffectiveness of choline serving as a methyl donor or
influencing methyltransferase expression in these cells.
Nutrition and Metabolic Insights 2016:9
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Figure 2. Methylation-related gene expression (A and C) and global CpG DNA methylation (B) in HepG2 and BeWo cells after 72 or 96 hours of cultivation
in different choline and glucose concentrations. LG–LC (black bars): low-glucose, low-choline; LG–HC (hatched bars): low-glucose, high-choline; HG–LC
(gray bars): high-glucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05.
Abbreviations: NS, not statistically significant; DNMT, DNA methyltransferase; BHMT, betaine-homocysteine S-methyltransferase; CHDH, choline dehydrogenase.

Choline supplementation altered lipid and glucose
metabolic genes in HepG2 cells. In HepG2 cells, both
choline and glucose supplementation increased (P , 0.05)
the expression of ACOX1, a gene that encodes the ACOX1
protein, which mediates fatty acid β-oxidation in the peroxisome (Fig. 3A).20 The HG–HC group had the highest expression compared to the other three groups. However, neither
FAS, which mediates de novo fatty acid synthesis, nor GPAT2,
which mediates triglyceride synthesis, was affected by glucose
or choline treatment. PEPCK, the rate-limiting enzyme in
the process of gluconeogenesis, was increased (P , 0.05) in
the HG–LC group compared to the LG–LC group. However, choline supplementation in the HG–HC group seemed
to normalize the elevation of PEPCK due to high glucose
(Fig. 3A). G6PD, the first enzyme in the pentose phosphate
pathway, was upregulated in the LG–HC group compared to
14
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the LG–LC group, but this effect of choline was not seen in the
high-glucose groups. The glucose transporter GLUT2, which
mediates hepatic glucose uptake, was upregulated (P , 0.05)
by high glucose regardless of choline supplementation.
No alterations in fatty acid or glucose metabolic gene expression as a result of choline supplementation were observed in BeWo
cells (Fig. 3B). High glucose decreased (P , 0.01) the expression
of the glucose transporter GLUT1 but increased (P , 0.05) the
expression of GPAT2 regardless of choline supplementation.
PEPCK was not expressed in the placenta (data not shown).

Discussion

We examined the interaction between choline and glucose
supplementations in modifying global DNA methylation
and expression of genes that mediate fatty acid and glucose metabolism in human placental and hepatic cell lines.

Effects of choline
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Figure 3. Glucose and fatty acid metabolic gene expression in HepG2 (A) and BeWo (B) cells after 72 or 96 hours of cultivation in different choline and
glucose concentrations. LG–LC (black bars): low-glucose, low-choline; LG–HC (hatched bars): low-glucose, high-choline; HG–LC (gray bars): highglucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05.
Abbreviations: NS, not statistically significant; ACOX1, peroxisomal acyl-coenzyme A oxidase 1; FAS, fatty acid synthase; GLUT, glucose transporter;
G6PD, glucose-6-phosphate dehydrogenase; GPAT2, glycerol-3-phosphate acyltransferase 2; PEPCK, phosphoenolpyruvate carboxykinase.

In HepG2 cells, choline supplementation seemed to promote DNA methylation regardless of glucose concentrations, whereas the changes in fatty acid and glucose metabolic
gene expression by choline supplementation may favor the
mitigation of hyperglycemic stress. BeWo cells were relatively
unresponsive to glucose or choline supplementation.
Effects of choline and glucose on cell growth differed
between cell lines. In HepG2 cells, choline appeared to be
a stronger promoting factor for cell growth and proliferation
than glucose, as both cell counts and the expression of the
cellular proliferative marker KI67 were increased by choline
supplementation. In contrast, in vitro hyperglycemia did
not alter HepG2 cell counts, which was consistent with
the observation by Iyer et al. 21 However, another study by
Chandrasekaran et al 22 suggests that when HepG2 cells
were supplemented with 50 mM glucose, they demonstrated
abnormal morphology, detachment from culture plates, and
apoptosis, which were not observed in this study. The differed

results may be due to the lower dose (35 mM) of glucose
used in our experiment, which seems to be well tolerated by
HepG2 cells. High glucose upregulated KI67, which was further amplified by choline cosupplementation. Previous studies suggest that hyperglycemia enhances liver stellate cell
proliferation and exacerbates collagen production and connective tissue overgrowth, which is a potential mechanism of
liver fibrosis. 23,24 It is unclear whether the growth and proliferation promoting effect of choline also applies to other liver
cell types and plays a role in liver damage. In vivo studies
in animals and humans, however, generally suggest choline
as a lipotrope that prevents the formation of fatty liver and
normalizes liver enzymes.8,25
High-glucose treatment tended to increase BeWo cell
counts modestly in the current study setting, although Weiss
et al 26 and Masumoto et al 27 both reported that trophoblast
growth was inhibited by in vitro hyperglycemia. Interestingly, expression of the cellular proliferative marker KI67 was
Nutrition and Metabolic Insights 2016:9
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significantly dampened in high glucose, whereas another proliferative marker PCNA was unchanged, despite the modest
increase in cell counts. These results may indicate that after
prolonged culture (96 hours) in high glucose, there was a larger
proportion of cells in the high-glucose groups that were not
proliferating compared to the low-glucose groups, since neither KI67 nor PCNA was expressed in resting (G0) cells.
Choline supplementation seemed to partially normalize the
overgrowth triggered by in vitro hyperglycemia, although it
did not affect KI67 expression. Taken together, both glucose
and choline have complicated roles in the growth and proliferation of BeWo cells.
Choline but not glucose treatment promoted DNA
methylation in HepG2 cells. CpG methylation of DNA is
a major epigenetic event that alters gene expression without
changing the genetic sequence. There is mounting evidence
suggesting that both global and site-specific CpG methylation levels are altered in patients with metabolic diseases, such
as diabetes. Zhao et al10 reported that leukocyte global CpG
methylation was positively associated with insulin resistance.
Pancreatic and duodenal homeobox 1 (PDX1), a critical gene
that promotes pancreatic cell maturation and islet function,
was hypermethylated in pancreatic islet cells isolated from
patients with type 2 diabetes.11 These findings highlight the
potential role of epigenetics in regulating the pathogenesis
and progression of diabetes. In a HepG2 cell culture model,
Chiang et al.28 demonstrated that in vitro hyperglycemia
increased DNMT3A expression and global CpG methylation, suggesting activation of the transmethylation cycle. Supplying additional methyl donors, such as choline, under the
condition of hyperglycemia may exacerbate the already active
transmethylation cycle. In this study, choline supplementation
increased DNMT expression and global CpG methylation in
HepG2 cells. However, in contrast to that reported by Chiang
et al, 28 global CpG methylation was not altered by glucose
treatment. Cosupplementation of choline and glucose seems
to have an additive effect on promoting DNMT expression
but not on global CpG methylation levels. It should be noted
that both CHDH and BHMT expression were decreased in
the HG–HC group. This may serve as a feedback mechanism
to prevent excess amounts of choline-derived methyl groups
from entering the transmethylation cycle when both glucose
and choline are in surplus, thereby maintaining CpG methylation levels despite the upregulation of DNMTs. Taken
together, supplementing choline in HepG2 cell culture did
not seem to exacerbate CpG hypermethylation under the condition of hyperglycemia.
In BeWo cells, DNMT expression was not altered by
either choline or glucose. The lack of BHMT expression in
these cells may explain the null effect of choline. However,
in an in vivo system, choline-derived methyl groups can be
transferred from the maternal compartment (eg, liver) to the
placenta. A previous human study has shown that higher
maternal choline intake increases both global and site-specific
16
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CpG methylation of the placenta.5 As such, in vivo studies
are needed to further discern the interaction of glucose and
choline on trophoblast CpG methylation in an integral
whole-body system.
Choline supplementation was not associated with
unfavorable alterations in fatty acid or glucose metabo
lism. Although fatty liver is associated with a higher risk
of insulin resistance, 29 recent studies suggest that fat accumulation in the liver itself does not always result in insulin
resistance.8,30–32 While choline deficiency results in fatty
liver, it improves insulin resistance and glucose tolerance
in male animals.7,8 The dissociation between fatty liver and
insulin resistance is proposed to be related to choline’s effect
on promoting the triglyceride breakdown and efflux of free
fatty acids from the liver to circulation.8 Circulating free fatty
acids exacerbate peripheral insulin resistance. In this study, we
found that choline supplementation enhanced the transcription of ACOX1 in HepG2 cells, especially in a high-glucose
environment. ACOX1 mediates the first step of long-chain
fatty acid β-oxidation in the peroxisome, and its increase
may upregulate fatty acid catabolism. 20 However, genes that
mediate de novo fatty acid synthesis (eg, FAS) or triglyceride
synthesis (eg, GPAT2) were not differentially expressed in the
high- or low-choline groups. These findings do not support
the role of choline in promoting triglyceride breakdown and
fatty acid output but rather indicate its effect on reducing fatty
acid content by enhancing β-oxidation.
Choline supplementation ameliorated the elevation
in PEPCK expression under the condition of high glucose.
Although glucose normally inhibits PEPCK expression and
reduces gluconeogenesis, chronic hyperglycemia blunts its
inhibitory effect, 33,34 leading to PEPCK overexpression and
an increased rate of gluconeogenesis, which is observed in
patients with type 2 diabetes. Our HepG2 cell model suggests
that choline supplementation may rectify PEPCK expression
when hepatocytes are exposed to high glucose, which may in
turn mitigate gluconeogenesis and hepatic glucose output.
Choline supplementation did not change glucose or fatty acid
metabolic gene expression in BeWo cells, likely due to the lack
of PEPCK expression and gluconeogenesis in these cells.
Glucose treatment triggered differential responses in
HepG2 and BeWo cells. While increased expression of
GLUT2 in HepG2 cells may enhance glucose uptake, there was
a decrease in GLUT1 expression in the high-glucose-treated
BeWo cells, which may be a mechanism of the trophoblasts to
prevent excessive glucose transfer under hyperglycemic stress.
The elevation of GPAT2 in BeWo cells in the high-glucose
groups may be an additional regulating mechanism to promote
triglyceride or phospholipid synthesis and trap free fatty acids
in the placenta, thereby preventing their transport to the fetus.
Taken together, these results suggest that choline supplementation do not adversely affect hepatic glucose and fatty acid
metabolism in either HepG2 cells or BeWo cells. Choline may
be used as a lipotropic supplementation to prevent or improve

Effects of choline

hepatic steatosis by improving fatty acid β-oxidation and may
lower the risk of hyperglycemia by dampening gluconeogenesis. The neutral effect of choline on placental-derived BeWo
cells discerns the concerns about its potential negative impacts
on the metabolic balance of pregnant women and their fetuses.
Nevertheless, clinical studies are needed to confirm the efficacy and safety of choline supplementation in modulating
macronutrient homeostasis in humans.

Conclusion

Choline supplementation increased DNA methylation and
modified the transcription of fatty acid and glucose metabolic
genes in HepG2 cells but did not have a direct effect on BeWo
cells. There was no indication that choline led to unfavorable
changes in the above processes under the condition of in vitro
hyperglycemia. In vivo studies are needed to further delineate
the interaction between choline and glucose in special physiological states, such as pregnancy.
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